• Kither Biotech

  Participated · Series B · Mar 2022

  Kither Biotech develops novel therapies for rare pulmonary diseases with a specific focus on cystic fibrosis (CF) and idiopathic pulmonary fibrosis (IPF). Its lead candidate, KIT2014, is a cell-permeable peptide designed to modulate intracellular cAMP levels and is being developed as an inhaled add-on therapy to improve outcomes for CF patients. The company plans to complete preclinical studies for KIT2014 in 2022 and to initiate a Phase 1/2A clinical trial thereafter. Kither is also launching preclinical development of KITCL27, a PI3K inhibitor pro-drug being developed as a monotherapy for IPF. The company is a spin-off from the University of Turin and collaborates with the Molecular Biotechnology Center and other research centres. Leadership includes CEO Dr. Vincent Metzler, CFO Marco Kevin Malisani (formerly CEO), and a board chaired by Laura Iris Ferro. Kither Biotech is a Turin-based biopharma spin-off from the University of Turin focused on identifying and developing drug candidates for pulmonary diseases, including cystic fibrosis, asthma, COPD and idiopathic pulmonary fibrosis. Its lead candidate, KIT-2014, is protected by a family of international patents and has received Orphan Drug designation from the European Medicines Agency. Preclinical results for KIT-2014 have been replicated in top centres active in cystic fibrosis research, including the University of Carolina at Chapel Hill. The company will use the new funds to complete preclinical studies and initiate a phase I/II clinical trial of KIT-2014 in healthy volunteers and patients during 2020. It also plans to advance a second development program testing another candidate for idiopathic pulmonary fibrosis and other respiratory diseases. Kither actively collaborates with the Molecular Biotechnology Center (University of Turin) and other research centres worldwide.

• Epicura

  Participated · Equity · Sep 2021

  EpiCura operates a nationwide platform that connects users to health and social care services at home through phone and video consultations and a long-term elderly care offering. The company provides a customized booking model that allows patients to book and receive services in under 24 hours, seven days a week. Since its 2017 founding, EpiCura has served over 3,000 families across more than ten cities and logged over 31,000 hours of services with a satisfaction rate close to 100%. The platform also handles recruitment and bureaucratic management for caregiving services, and in December 2020 introduced night, continuous and cohabiting caregiver solutions. With approximately €8 million in total funding to date, the company plans to expand nationally into new key cities, add new services and invest in further development of its digital health platform and team.

No current team members are available.